MagneSensors'program is aimed at developing next generation magnetic nanoparticle labels tailored specifically for ultra-sensitive magnetic assays. These magnetic nanoparticles will be used to detect bacteria leading to sepsis, where there is a strong need for reliable diagnostic tests that are sensitive, specific, and fast. The project takes advantage of an innovative magnetic detection platform where magnetic nanoparticles are attached to antibodies that bind with high specificity to surface antigens on target bacteria. An extremely sensitive magnetic sensor, consisting of a patented high temperature superconducting quantum interference device (SQUID), quantitatively measures the number of magnetic labels bound to the bacteria, and hence the number of bacteria in a sample. These optimized magnetic nanoparticles will enable high sensitivity detection in whole blood using a simple mix and measure format, which is not possible with competing methods. Moreover, the tests can be automated for high throughput and low cost. There is a major emphasis on high sensitivity to enable diagnosis of the pathogen at the earliest possible stage. While the initial focus is on a ""proof-of-concept"" for the detection of E. coli O157:H7, the platform is applicable to a wide range of bacteria. Sepsis is the tenth-leading cause of death in the U.S. and the second-leading cause of death in non- coronary intensive care unit patients. Existing diagnostic tests are inadequate and there is a large market opportunity available for superior tests, as the health care problem is significant. Note that while competing amplified nucleic acid tests can achieve the necessary sensitivity, there are many challenges to achieving it on clinical specimens. Drawbacks include false positives due to contamination as well as longer turnaround times and other issues that hamper its reliable use for the clinical diagnosis of life threatening infections. The Phase I aims are: 1) to synthesize magnetic nanoparticle labels that have over 50X larger signal (compared to currently used magnetic nanoparticles) and which are stable in blood, and 2) demonstrate sensitive detection of bacteria to 250 CFU/ml in a 45-minute, mix and measure assay in whole blood. In Phase II the sensitivity will be improved further to <50 CFU/ml in as little as 15-20 minutes total assay time, and include additional relevant organisms such as S. aureus along with testing on clinical samples. Magnetic nanoparticles with a larger magnetic signal will be synthesized by increasing the overall volume of the magnetic core as well as the size of the magnetite crystals comprising the core. Minimal aggregation and non-specific binding are critical for stability in whole blood, which is necessarily more difficult for powerful magnetic nanoparticles due to their larger attractive forces. To achieve this stability, we will modify the nanoparticle surface using a method we have developed and successfully employed in prior work.
Public Health Relevance: Sepsis is the tenth-leading cause of death in the U.S., the second-leading cause of death in non-coronary intensive care unit patients, and costs the health care system over $17 billion annually. The ensuing overuse of antibiotics has further resulted in antibiotic-resistant strains of bacteria, significantly increasing the risk of sepsis from hospital-acquired infections, particularly those from post-operative wound, trauma, and the urinary tract. The proposed effort is ultimately focused on rapid, ultra-sensitive diagnostic tests for bacteria that lead to sepsis, enabling the pathogen to be identified at the earliest possible stage to permit timely treatment with the correct antibiotic.
Thesaurus Terms: Antibiotic Agents;Antibiotic Drugs;Antibiotic Resistance;Antibiotics;Antibodies;Assay;Bacteria;Binding;Binding (Molecular Function);Bioassay;Biologic Assays;Biological Assay;Blood;Blood Reticuloendothelial System;Cancer Detection;Cause Of Death;Cell Communication And Signaling;Cell Signaling;Cell Surface Antigens;Clinical;Coronary Care Units;Custom;Data;Detection;Development;Diagnosis;Diagnostic;Diagnostic Tests;E Coli O157;Escherichia Coli O157;Generations;Goals;Health Care Systems;Healthcare;Healthcare Systems;High Temperature Of Physical Object;Hospital Infections;Hospital Acquired Infection;Hospitals;Hour;Immunologic Surface Markers;Immunological Surface Markers;Infection;Intensive Care Units;Intracellular Communication And Signaling;Label;Laboratories;Lead;Legal Patent;Life;Macrogols;Magnetism;Manufacturer;Manufacturer Name;Marketing;Measurement;Measures;Methods;Miscellaneous Antibiotic;Molecular Interaction;Nosocomial Infections;Nucleic Acid Amplification Tests;Nucleic Acid Testing;Organism;Patents;Patients;Pb Element;Phase;Polyethylene Glycols;Polyethylene Oxide;Polyethyleneoxide;Polyoxyethylenes;Post-Operative;Postoperative;Postoperative Period;Preparation;Reagent;Research Specimen;Resistance To Antibiotics;Resistant To Antibiotics;Risk;Running;S. Aureus;S.Aureus;Sampling;Sepsis;Signal Transduction;Signal Transduction Systems;Signaling;Sorting - Cell Movement;Specificity;Specimen;Staging;Staphylococcus Aureus;Strepavidin;Streptavidin;Surface;Surface Antigens;Testing;Time;Trauma;Urinary Tract;Whole Blood;Work;Antibiotic Resistant;Base;Biological Signal Transduction;Bloodstream Infection;Clinical Diagnosis;Clinical Relevance;Clinically Relevant;Commercial Application;Coronary Intensive Care;Cost;Design;Designing;Developmental;Experience;Health Care;Heavy Metal Pb;Heavy Metal Lead;High Temperature;Improved;Innovate;Innovation;Innovative;Innovative Technologies;Institutional Infection;Instrument;Living System;Magnetic;Magnetic Cell Separation;Magnetic Cell Separation System;Magnetite;Magnetite Ferrosoferric Oxide;Nano Particle;Nanoparticle;Next Generation;Pathogen;Programs;Resistance Strain;Resistant Strain;Sensor;Sorting;Stem;Superconducting Quantum Interference Device;Wound
